• Lamotrigine: Mechanistic Insights and Strategic Pathways ...

  2026-01-21

  This thought-leadership article examines Lamotrigine, a dual sodium channel blocker and 5-HT inhibitor, through the lens of mechanistic advances and translational strategy. It contextualizes recent evidence on serotonergic metabolism, guides experimental assay design, and positions APExBIO’s high-purity Lamotrigine as an essential tool for epilepsy and cardiac sodium current research—offering a roadmap for researchers aiming to bridge in vitro validation and clinical relevance.

• Tropifexor: FXR Agonist Workflow Enhancements for Epithel...

  2026-01-21

  Tropifexor (LJN452) is a next-gen small molecule FXR agonist powering reproducible breakthroughs in intestinal epithelial barrier and metabolic disease research. This practical guide details optimized experimental workflows, advanced applications, and troubleshooting strategies, making Tropifexor from APExBIO the cornerstone tool for high-impact FXR signaling studies.

• Unlocking Reliable DNA Repair Research with BMN 673 (Tala...

  2026-01-20

  This in-depth article provides scenario-driven guidance for optimizing cell viability and DNA repair assays using BMN 673 (Talazoparib) Potent PARP1/2 Inhibitor (SKU A4153). Drawing on validated protocols, recent literature, and practical lab challenges, it demonstrates how this selective PARP inhibitor advances reproducibility and data integrity in homologous recombination deficient cancer research.

• Protease Inhibitor Cocktail (MS-SAFE): Precision Protease...

  2026-01-20

  Explore how the Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) advances protein degradation prevention in proteomics and biochemical research. Delve into its unique MS-compatibility, mechanistic depth, and emerging applications in stem cell and signaling studies.

454 records 31/31 page Previous First page 上5页 31